The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved lung function by 160 mL at 52 weeks.
After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...
Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...
Dupilumab in COPD was associated with decreased risk of mortality, emergency visits, exacerbations, and respiratory failure and infections.
The risk for all-cause death was higher in older adults with chronic obstructive pulmonary disease (COPD) who experienced social isolation compared to those who were more socially connected to ...
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations ...
Dupixent looks well positioned to reach peak ... and strong clinical data in chronic obstructive pulmonary disease (COPD) will help the drug serve additional patients. While Sanofi shares profits ...
Research has linked poverty to COPD and its related comorbidities, which for many individuals with COPD includes cardiovascular disease, osteoporosis, and metabolic disorders like diabetes.
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. This expansion positions Dupixent as the first targeted therapy for ...
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. This expansion positions Dupixent as the first targeted therapy for COPD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback